Saffron Supplements: What It Is, If It Works & What to Buy

Saffron Benefits: What the Evidence Actually Supports

Want a product that actually matches the studied dose? See our saffron picks ranked by disclosed standardization and cost per day →

Depression: the evidence that made saffron notable

This is the benefit that separates saffron from most botanicals. A 2019 meta-analysis pooling nine trials found 30 mg/day of standardized saffron extract beat placebo for mild-to-moderate depressive symptoms with a large effect size (Tóth 2019). A separate 2019 meta-analysis of 23 studies found the same pattern — a large effect versus placebo (g = 0.99) and an even larger effect when saffron was added on top of an existing antidepressant (g = 1.23) — though it also flagged evidence of publication bias (Marx 2019). In small, six-to-eight-week head-to-head pilot trials, 30 mg/day of saffron performed comparably to fluoxetine 20 mg/day (Noorbala 2005) and imipramine 100 mg/day (Akhondzadeh 2004). Here's the honest caveat, stated plainly: these trials are mostly small (30–60 people), short, overwhelmingly run in Iran, and some carry funding conflicts — "works like an SSRI" overstates a promising but fragile evidence base. Full breakdown, including where the effect gets weaker depending on which rating scale is used: does saffron help depression? — the honest evidence.

Anxiety: a real but secondary signal

Anxiety relief shows up mostly as a secondary outcome inside the depression trials rather than as its own dedicated research line. The same 23-study meta-analysis cited above found saffron produced a large effect versus placebo on anxiety symptoms too (g = 0.95, Marx 2019). That's a meaningful signal, but it comes from the same small, short, Iran-concentrated trial base as the depression evidence, measured with the same mood-trial designs rather than anxiety-specific protocols. Treat it as encouraging, not established.

ADHD: an emerging adjunct, mostly in children

The most surprising secondary finding: in a 6-week randomized, double-blind pilot trial, saffron capsules dosed by weight (20–30 mg/day) performed no differently than methylphenidate on parent- and teacher-rated ADHD symptom scales in 50 children who completed the trial, with a similar rate of side effects between groups (Baziar 2019). A 2024 systematic review pooling four clinical trials (118 patients total) concluded saffron showed an "efficient role" either as an add-on to methylphenidate or as monotherapy against ADHD, without significant safety issues, while explicitly calling for larger, better-designed multicenter studies (Seyedi-Sahebari 2024). This is a real, growing signal — but it's four small trials, mostly short-term, from a narrow set of research groups. Don't substitute it for a prescribed ADHD medication without your child's prescriber involved.

Appetite and snacking: a different extract, a thinner claim

This one gets conflated with the mood dose, and shouldn't be. The appetite research used Satiereal, a proprietary saffron stigma extract, at 176.5 mg/day — roughly six times the 30 mg mood dose. In a single placebo-controlled trial of 60 mildly overweight women, Satiereal reduced snacking frequency and produced a modestly greater body-weight reduction than placebo over 8 weeks (Gout 2010). It's one industry-funded trial of one specific branded extract at a much higher dose than what's studied for mood, so it does not support the idea that a standard 30 mg saffron capsule curbs appetite.

Eye health: an early, physiological signal in AMD

In a small crossover trial, 25 people with early age-related macular degeneration took 20 mg/day of saffron or placebo for three months, then switched. Saffron supplementation improved retinal flicker sensitivity (a functional measure of macular health) compared with both baseline and the placebo period (Falsini 2010). That's a real, measured physiological effect — but it's one small trial measuring a functional marker, not vision outcomes like visual acuity, and the authors themselves called for replication before drawing clinical conclusions.

None of this matters if it isn't real saffron

Saffron is the most adulterated spice in the world — a 2026 systematic review estimated 20–30% of commercial saffron is adulterated globally, with rates as high as ~60% in some markets (Mehdizadeh 2026). Every benefit above was studied using a standardized extract with disclosed crocin or safranal content — not a bare "saffron extract" of unknown potency. A cheap product with no disclosed standardization isn't a discount version of what was studied; it may not be meaningfully related to it at all. Full method for checking: is your saffron real?